Biochemical recurrence of prostate cancer: The controversial recognition and management

Chinese Medical Journal

Volumn 124, Issue 9, 2011, Pages 1283-1285

  Xia, Shu Jie ^a   Jing, Yi Feng ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BONE SCINTISCANNING; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; GLEASON SCORE; HUMAN; INTERVENTION STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RECURRENT CANCER; RISK FACTOR; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME; TUMOR GROWTH;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 79955935132     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.09.001     Document Type: Editorial

References (28)

1. Presti JC Jr, Shinohara K, Bacchetti P, Tigrani V, Bhargava V. Positive fraction ofsystematic biopsies predicts risk of relapse after radical prostatectomy. Urology 1998; 52: 1079-1084.
2. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.
3. Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol 2002; 168: 110-115.
4. Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 2001; 166: 1322-1327.
5. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165: 1146-1151.
6. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003; 61: 365-369.
7. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, et al. EAU guidelines on prostate cancer. Eur Urol 2005; 48: 546-551.
8. Ferguson RA, Yu H, Kalyvas M, Zammit S, Diamandis EP. Ultrasensitive detection of prostate-specific antigen by a timeresolved immunofluorometric assay and the immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem 1996; 42: 675-684.
9. American Society for Therapeutic Radiology, Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035-1041.
10. Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (''trifecta''). Urology 2005; 66: 83-94.
11. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011; Epub ahead of print.
12. D'Amico AV, Moul J, Carrol PR, Sun L, Lubeck D, Chen M. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004; 172: 42-47.
13. Perlmutter MA, Lepor H. Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy. Urology 2008; 71: 501-505.
14. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-962.
15. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 2007; 25: 2225-2229.
16. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-578.
17. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-449.
18. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-2930.
19. Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003; 61: 607-611.
20. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035-2041.
21. Wiegel T, Lohm G, Bottke D, Hocht S, Miller K, Siegmann A, et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome: results of a retrospective study. Int J Radiat Oncol Biol Phys 2009; 73: 1009-1016.
22. Moreira DM, Jayachandran J, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, et al. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database. BJU Int 2009; 104: 1452-1456.
23. Tomita N, Kodaira T, Furutani K, Tachibana H, Nakahara R, Mizoguchi N, et al. Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy. J Cancer Res Clin Oncol 2009; 135: 1561-1567.
24. Jacinto AA, Fede AB, Fagundes LA, Salvajoli JV, Castilho MS, Viani GA, et al. Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy. Radiat Oncol 2007; 2: 8.
25. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with nodepositive prostate cancer. N Engl J Med 1999; 341: 1781-1788.
26. Messing EM, Manola J, Yao J, Kieman M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-479.
27. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171: 1141-1147.
28. Ide H, Nakashima J, Kono H, Kikuchi E, Nagata H, Miyajima A, et al. Prognostic stratification in patients who received hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy. Jpn J Clin Oncol 2010; 40: 177-180.